OncoSec to Present at the 22nd Annual Oppenheimer Healthcare Conference

SAN DIEGO, Dec. 9, 2011 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), a biotechnology company developing advanced-stage OMS ElectroOncology therapies to treat skin cancer and other solid tumor cancers, today announces that Punit Dhillon, President and CEO, will be presenting at the 22nd Annual Oppenheimer Healthcare Conference.

(Logo:  http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

22nd Annual Oppenheimer Healthcare Conference
The Waldorf Astoria
301 Park Avenue
New York, New York 10022
December 13-14, 2011

OncoSec Presentation
December 13, 2011
3:20 pm ET

A live and archived webcast will be accessible on OncoSec's website www.oncosec.com

To arrange a meeting with management please contact Adam Holdsworth, The Investor Relations Group 212-285-3210 [email protected]

The Oppenheimer 22nd Annual Healthcare Conference will take place at the historic Waldorf Astoria in New York City. This conference will showcase leading public and private companies specializing in sectors such as biotechnology, medical device, pharmaceutical, diagnostics, healthcare tools, facility and distribution. Attendees will be given opportunities to connect to company leaders through formal presentations, panels and one-on-ones giving insight into current healthcare topics of interest from development of new blockbuster pharmaceutical and biotechnology products to Food and Drug Administration policy, M&A environment, and healthcare reform and impact.

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec's clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy. More information is available at www.oncosec.com. Additional information may also be found at OncoSec's Facebook, Twitter, and LinkedIn sites.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

SOURCE OncoSec Medical Incorporated